Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741240 | 0.88 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL555073 | 0.86 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL18522430 | 0.86 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL30759207 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL30114700 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL1635061 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL13748300 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL28390904 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL3229288 | 0.82 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL23155544 | 0.81 | NAMPT (0.46) | NAMPTCYP17A1RAB9AATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3894416-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | Global Blood Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-1076058-A1 | $g(b)-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-02-14 | — | — | EP | disclosed |
| EP-0495584-B1 | Cephalosporin compounds and their pharmaceutical compositions | LILLY CO ELI (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5637693-A | CEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5362722-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| US-5247073-A | Antibiotics for bactericides | ELI LILLY AND COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| CN-1063284-A | Antiseptic-germicide | LILLY CO ELI (US) | 1992-08-05 | — | — | CN | disclosed |
| CN-1063286-A | Antiseptic-germicide | LILLY CO ELI (US) | 1992-08-05 | — | — | CN | disclosed |
| EP-0495584-A2 | Cephalosporin compounds and their pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 1992-07-22 | — | — | EP | disclosed |
| EP-0495585-A1 | Antibacterial agents | ELI LILLY AND COMPANY (US) | 1992-07-22 | — | — | EP | disclosed |
| US-5077287-A | Treating infectious diseases in man and animals | ELI LILLY AND COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | NAMPT 1249/4885CYP17A1 2173/4885RAB9A 2873/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | NAMPT 351/4885CYP17A1 2367/4885RAB9A 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.